Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL
Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.
Dr. Cheah on the Safety Profile of TG-1701 With and Without Ublituximab/Umbralisib in CLL
Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.
Dr. Cheah on the Efficacy of TG-1701 Alone and in Combination With U2 in CLL
Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.
Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on Checkpoint Inhibitor and VEGF TKI
Talazoparib Plus Enzalutamide Has Manageble Toxicity With Dose Modifications, Supportive Care in mCRPC
Real-World Data Detail Potential Benefits of Darolutamide Over Other ARIs in nmCRPC
Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC
2 Clarke Drive Cranbury, NJ 08512